99 related articles for article (PubMed ID: 32810752)
1. A low toxic CRM1 degrader: Synthesis and anti-proliferation on MGC803 and HGC27.
Xu HW; Jia S; Liu M; Li X; Meng X; Wu X; Yu L; Wang M; Jin CY
Eur J Med Chem; 2020 Nov; 206():112708. PubMed ID: 32810752
[TBL] [Abstract][Full Text] [Related]
2. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
[TBL] [Abstract][Full Text] [Related]
4. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
Liu S; Qiao W; Sun Q; Luo Y
J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
[TBL] [Abstract][Full Text] [Related]
5. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
6. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.
Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T
Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782
[TBL] [Abstract][Full Text] [Related]
7. Leptomycin B inhibits the proliferation, migration, and invasion of cultured gastric carcinoma cells.
Zhu H; Yang Y; Wang L; Xu X; Wang T; Qian H
Biosci Biotechnol Biochem; 2020 Feb; 84(2):290-296. PubMed ID: 31619134
[TBL] [Abstract][Full Text] [Related]
8. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
[TBL] [Abstract][Full Text] [Related]
10. CRM1 as a new therapeutic target for non-Hodgkin lymphoma.
Han X; Wang J; Shen Y; Zhang N; Wang S; Yao J; Shi Y
Leuk Res; 2015 Jan; 39(1):38-46. PubMed ID: 25466285
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity of (R)-4'-methylklavuzon on hepatocellular carcinoma cells and EpCAM
Delman M; Avcı ST; Akçok İ; Kanbur T; Erdal E; Çağır A
Eur J Med Chem; 2019 Oct; 180():224-237. PubMed ID: 31306909
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
13. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
14. Targeting the nuclear transport machinery by rational drug design.
Mao L; Yang Y
Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy.
Gao W; Lu C; Chen L; Keohavong P
J Thorac Oncol; 2015 May; 10(5):815-825. PubMed ID: 25629636
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma.
van der Watt PJ; Zemanay W; Govender D; Hendricks DT; Parker MI; Leaner VD
Oncol Rep; 2014 Aug; 32(2):730-8. PubMed ID: 24898882
[TBL] [Abstract][Full Text] [Related]
17. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
Salas Fragomeni RA; Chung HW; Landesman Y; Senapedis W; Saint-Martin JR; Tsao H; Flaherty KT; Shacham S; Kauffman M; Cusack JC
Mol Cancer Ther; 2013 Jul; 12(7):1171-9. PubMed ID: 23615632
[TBL] [Abstract][Full Text] [Related]
18. The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.
Abeykoon JP; Paludo J; Nowakowski KE; Stenson MJ; King RL; Wellik LE; Wu X; Witzig TE
Blood Cancer J; 2019 Feb; 9(3):24. PubMed ID: 30808874
[No Abstract] [Full Text] [Related]
19. Understanding XPO1 target networks using systems biology and mathematical modeling.
Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
[TBL] [Abstract][Full Text] [Related]
20. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.
Ortega JF; de Conti A; Tryndyak V; Furtado KS; Heidor R; Horst MA; Fernandes LH; Tavares PE; Pogribna M; Shpyleva S; Beland FA; Pogribny IP; Moreno FS
Oncotarget; 2016 Apr; 7(17):24339-47. PubMed ID: 27013579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
